A retrospective analysis after low-dose-rate prostate brachytherapy with permanent 125I seed implant

Clinical and dosimetric results in 70 patients

Costanza Chiumento, Antonietta Montagna, Stefania Clemente, Mariella Cozzolino, Vincenzo Fusco

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims and background. To evaluate the biochemical disease-free survival (bDFS) rate after 125I permanent-implant prostate brachytherapy. Methods. Patients with a diagnosis of prostate adenocarcinoma and adequate PSA follow-up were selected for this retrospective study. Brachytherapy with permanent 125I seeds was performed as monotherapy, with a prescribed dose of 145 Gy to the prostate. Patients were stratified into recurrence risk groups according to the National Comprehensive Cancer Network (NCCN) guidelines. Biochemical failure was defined using the American Society of Therapeutic Radiology and Oncology (ASTRO) guidelines. The post-implant D90 (defined as the minimum dose covering 90% of the prostate) was obtained for each patient. Two cutoff points were used to test the correlation between D90 and bDFS results: 130 Gy and 140 Gy. bDFS was calculated from the implant date to the date of biochemical recurrence. Univariate and multivariate analysis were performed using the SPSS software and included clinical stage, pretreatment PSA, Gleason score (GS), androgen deprivation therapy, D90, and risk groups. In the univariate analysis we used a cutoff point of 5.89 ng/mL for PSA and 5 for GS. Results. From June 2003 to April 2007, 70 patients were analyzed. The patients' distribution into recurrence risk groups was as follows: 39 patients (56%) in the low-risk group, 23 patients (33%) in the intermediate-risk group, and 8 patients (11%) in the high-risk group. At a median follow-up of 47 months (range, 19-70 months) bDFS was 88.4%, with a global actuarial 5-year bDFS of 86%. Disease-related factors including initial PSA level, GS and risk group were significant predictors of biochemical failure (P = 0.01, P = 0.01, P = 0.006, respectively). In multivariate analysis, risk group (P = 0.005) and GS (P = 0.03) were statistically significant. Conclusion. Our data are in agreement with those in the literature and, despite the short follow-up, confirm the advantage of brachytherapy for patients at low and intermediate risk of recurrence.

Original languageEnglish
Pages (from-to)335-340
Number of pages6
JournalTumori
Volume97
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

Brachytherapy
Prostate
Seeds
Neoplasm Grading
Disease-Free Survival
Recurrence
Multivariate Analysis
Guidelines
Radiation Oncology
Androgens
Adenocarcinoma
Software
Survival Rate
Retrospective Studies

Keywords

  • Biochemical disease-free survival
  • Prostate brachytherapy
  • Prostate-specific antigen
  • Risk groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A retrospective analysis after low-dose-rate prostate brachytherapy with permanent 125I seed implant : Clinical and dosimetric results in 70 patients. / Chiumento, Costanza; Montagna, Antonietta; Clemente, Stefania; Cozzolino, Mariella; Fusco, Vincenzo.

In: Tumori, Vol. 97, No. 3, 05.2011, p. 335-340.

Research output: Contribution to journalArticle

Chiumento, Costanza ; Montagna, Antonietta ; Clemente, Stefania ; Cozzolino, Mariella ; Fusco, Vincenzo. / A retrospective analysis after low-dose-rate prostate brachytherapy with permanent 125I seed implant : Clinical and dosimetric results in 70 patients. In: Tumori. 2011 ; Vol. 97, No. 3. pp. 335-340.
@article{fd6a20b7d85b4b918244f388d38b5fd6,
title = "A retrospective analysis after low-dose-rate prostate brachytherapy with permanent 125I seed implant: Clinical and dosimetric results in 70 patients",
abstract = "Aims and background. To evaluate the biochemical disease-free survival (bDFS) rate after 125I permanent-implant prostate brachytherapy. Methods. Patients with a diagnosis of prostate adenocarcinoma and adequate PSA follow-up were selected for this retrospective study. Brachytherapy with permanent 125I seeds was performed as monotherapy, with a prescribed dose of 145 Gy to the prostate. Patients were stratified into recurrence risk groups according to the National Comprehensive Cancer Network (NCCN) guidelines. Biochemical failure was defined using the American Society of Therapeutic Radiology and Oncology (ASTRO) guidelines. The post-implant D90 (defined as the minimum dose covering 90{\%} of the prostate) was obtained for each patient. Two cutoff points were used to test the correlation between D90 and bDFS results: 130 Gy and 140 Gy. bDFS was calculated from the implant date to the date of biochemical recurrence. Univariate and multivariate analysis were performed using the SPSS software and included clinical stage, pretreatment PSA, Gleason score (GS), androgen deprivation therapy, D90, and risk groups. In the univariate analysis we used a cutoff point of 5.89 ng/mL for PSA and 5 for GS. Results. From June 2003 to April 2007, 70 patients were analyzed. The patients' distribution into recurrence risk groups was as follows: 39 patients (56{\%}) in the low-risk group, 23 patients (33{\%}) in the intermediate-risk group, and 8 patients (11{\%}) in the high-risk group. At a median follow-up of 47 months (range, 19-70 months) bDFS was 88.4{\%}, with a global actuarial 5-year bDFS of 86{\%}. Disease-related factors including initial PSA level, GS and risk group were significant predictors of biochemical failure (P = 0.01, P = 0.01, P = 0.006, respectively). In multivariate analysis, risk group (P = 0.005) and GS (P = 0.03) were statistically significant. Conclusion. Our data are in agreement with those in the literature and, despite the short follow-up, confirm the advantage of brachytherapy for patients at low and intermediate risk of recurrence.",
keywords = "Biochemical disease-free survival, Prostate brachytherapy, Prostate-specific antigen, Risk groups",
author = "Costanza Chiumento and Antonietta Montagna and Stefania Clemente and Mariella Cozzolino and Vincenzo Fusco",
year = "2011",
month = "5",
doi = "10.1700/912.10031",
language = "English",
volume = "97",
pages = "335--340",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - A retrospective analysis after low-dose-rate prostate brachytherapy with permanent 125I seed implant

T2 - Clinical and dosimetric results in 70 patients

AU - Chiumento, Costanza

AU - Montagna, Antonietta

AU - Clemente, Stefania

AU - Cozzolino, Mariella

AU - Fusco, Vincenzo

PY - 2011/5

Y1 - 2011/5

N2 - Aims and background. To evaluate the biochemical disease-free survival (bDFS) rate after 125I permanent-implant prostate brachytherapy. Methods. Patients with a diagnosis of prostate adenocarcinoma and adequate PSA follow-up were selected for this retrospective study. Brachytherapy with permanent 125I seeds was performed as monotherapy, with a prescribed dose of 145 Gy to the prostate. Patients were stratified into recurrence risk groups according to the National Comprehensive Cancer Network (NCCN) guidelines. Biochemical failure was defined using the American Society of Therapeutic Radiology and Oncology (ASTRO) guidelines. The post-implant D90 (defined as the minimum dose covering 90% of the prostate) was obtained for each patient. Two cutoff points were used to test the correlation between D90 and bDFS results: 130 Gy and 140 Gy. bDFS was calculated from the implant date to the date of biochemical recurrence. Univariate and multivariate analysis were performed using the SPSS software and included clinical stage, pretreatment PSA, Gleason score (GS), androgen deprivation therapy, D90, and risk groups. In the univariate analysis we used a cutoff point of 5.89 ng/mL for PSA and 5 for GS. Results. From June 2003 to April 2007, 70 patients were analyzed. The patients' distribution into recurrence risk groups was as follows: 39 patients (56%) in the low-risk group, 23 patients (33%) in the intermediate-risk group, and 8 patients (11%) in the high-risk group. At a median follow-up of 47 months (range, 19-70 months) bDFS was 88.4%, with a global actuarial 5-year bDFS of 86%. Disease-related factors including initial PSA level, GS and risk group were significant predictors of biochemical failure (P = 0.01, P = 0.01, P = 0.006, respectively). In multivariate analysis, risk group (P = 0.005) and GS (P = 0.03) were statistically significant. Conclusion. Our data are in agreement with those in the literature and, despite the short follow-up, confirm the advantage of brachytherapy for patients at low and intermediate risk of recurrence.

AB - Aims and background. To evaluate the biochemical disease-free survival (bDFS) rate after 125I permanent-implant prostate brachytherapy. Methods. Patients with a diagnosis of prostate adenocarcinoma and adequate PSA follow-up were selected for this retrospective study. Brachytherapy with permanent 125I seeds was performed as monotherapy, with a prescribed dose of 145 Gy to the prostate. Patients were stratified into recurrence risk groups according to the National Comprehensive Cancer Network (NCCN) guidelines. Biochemical failure was defined using the American Society of Therapeutic Radiology and Oncology (ASTRO) guidelines. The post-implant D90 (defined as the minimum dose covering 90% of the prostate) was obtained for each patient. Two cutoff points were used to test the correlation between D90 and bDFS results: 130 Gy and 140 Gy. bDFS was calculated from the implant date to the date of biochemical recurrence. Univariate and multivariate analysis were performed using the SPSS software and included clinical stage, pretreatment PSA, Gleason score (GS), androgen deprivation therapy, D90, and risk groups. In the univariate analysis we used a cutoff point of 5.89 ng/mL for PSA and 5 for GS. Results. From June 2003 to April 2007, 70 patients were analyzed. The patients' distribution into recurrence risk groups was as follows: 39 patients (56%) in the low-risk group, 23 patients (33%) in the intermediate-risk group, and 8 patients (11%) in the high-risk group. At a median follow-up of 47 months (range, 19-70 months) bDFS was 88.4%, with a global actuarial 5-year bDFS of 86%. Disease-related factors including initial PSA level, GS and risk group were significant predictors of biochemical failure (P = 0.01, P = 0.01, P = 0.006, respectively). In multivariate analysis, risk group (P = 0.005) and GS (P = 0.03) were statistically significant. Conclusion. Our data are in agreement with those in the literature and, despite the short follow-up, confirm the advantage of brachytherapy for patients at low and intermediate risk of recurrence.

KW - Biochemical disease-free survival

KW - Prostate brachytherapy

KW - Prostate-specific antigen

KW - Risk groups

UR - http://www.scopus.com/inward/record.url?scp=79960877010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960877010&partnerID=8YFLogxK

U2 - 10.1700/912.10031

DO - 10.1700/912.10031

M3 - Article

VL - 97

SP - 335

EP - 340

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -